- Home
- NZF vs AMRX Comparison
NZF vs AMRX Comparison
Compare NZF & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- AMRX
- Stock Information
- Founded
- NZF 2001
- AMRX 2002
- Country
- NZF United States
- AMRX United States
- Employees
- NZF N/A
- AMRX N/A
- Industry
- NZF Finance Companies
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- NZF Finance
- AMRX Health Care
- Exchange
- NZF Nasdaq
- AMRX Nasdaq
- Market Cap
- NZF 2.5B
- AMRX 2.7B
- IPO Year
- NZF N/A
- AMRX N/A
- Fundamental
- Price
- NZF $12.89
- AMRX $8.46
- Analyst Decision
- NZF
- AMRX Strong Buy
- Analyst Count
- NZF 0
- AMRX 6
- Target Price
- NZF N/A
- AMRX $9.00
- AVG Volume (30 Days)
- NZF 496.8K
- AMRX 1.1M
- Earning Date
- NZF 01-01-0001
- AMRX 11-08-2024
- Dividend Yield
- NZF 4.67%
- AMRX N/A
- EPS Growth
- NZF N/A
- AMRX N/A
- EPS
- NZF N/A
- AMRX N/A
- Revenue
- NZF N/A
- AMRX $2,597,992,000.00
- Revenue This Year
- NZF N/A
- AMRX $17.40
- Revenue Next Year
- NZF N/A
- AMRX $3.10
- P/E Ratio
- NZF N/A
- AMRX N/A
- Revenue Growth
- NZF N/A
- AMRX 12.37
- 52 Week Low
- NZF $9.82
- AMRX $3.36
- 52 Week High
- NZF $12.29
- AMRX $8.95
- Technical
- Relative Strength Index (RSI)
- NZF 47.21
- AMRX 48.40
- Support Level
- NZF $12.82
- AMRX $8.43
- Resistance Level
- NZF $12.97
- AMRX $8.95
- Average True Range (ATR)
- NZF 0.08
- AMRX 0.25
- MACD
- NZF -0.02
- AMRX -0.01
- Stochastic Oscillator
- NZF 15.48
- AMRX 47.87
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.